Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)

Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027.

JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117.

Ultragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025.

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety profile is favorable. Phase 3 study planned for 2025.

Biogen previously decided against opting into Ionis' Angelman program.

With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.